]>
IRCT20251213068301N1 IRCT 2025-12-25 Qazvin University of Medical Sciences Comparative study of the lipids effects of telmisartan and valsartan in patients with STEMI Comparative study of the lipids effects of telmisartan and valsartan in patients with STEMI 2026-01-20 anticipated 248 Recruiting https://irct.ir/trial/88066 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: This study was an open-label randomized clinical trial. 4 Myocardial infarction (MI). Intervention 1: Intervention group: Telmisartan. Intervention 2: Intervention group: Valsartan. Yes - There is a plan to make this available What will be shared: Document / Data Title Deidentified Data of Patients with STEMI in the Telmisartan and Valsartan Comparison Trial Document / Data Details Participant personal data including baseline demographic information, baseline clinical characteristics, metabolic laboratory parameters (lipid profile and blood glucose indicators), and primary outcome variables of the study will be potentially shareable after all identifying and de-identifying information has been removed. Data sharing will be limited to data related to the primary and secondary outcomes of the study, and raw patient identifying information (including name, national code, case number, or contact information) will not be provided at any stage. Access to data will only be possible upon written request from researchers and after approval by the investigator responsible for the study. When: De-identified participant data will be available to eligible researchers for 6 months after the publication of the main study results and for 5 years. To whom: De-identified data of participants will be accessible to eligible researchers. These individuals include researchers working in academic and research institutions as well as independent researchers, provided that they submit a written request and their research purpose is approved by the investigator responsible for the study. Access to data for commercial or industrial purposes is not possible without the written consent of the investigator responsible for the study. Conditions: De-identified data and study documentation are authorized for use only for research and scientific analyses related to the metabolic effects of telmisartan and valsartan in patients with STEMI. Requests for access to data must be made in writing, stating the specific research purpose, and will be made available upon approval by the study investigator. Use of data for commercial, promotional, or any non-scientific publication is prohibited. Applicant researchers are required to keep all data de-identified and confidential after use and to cite any publication of results to the original study. Where to obtain: All requests for access to de-identified data and study documentation should be sent to the study investigator: Name and title: Dr. Majid Haji Karimi (principal investigator) Center: Bu-Ali Sina Educational and Therapeutic Center, Qazvin, Iran Postal address: Iran-Qazvin Province-Qazvin City-Bu-Ali St.-Bu-Ali Sina Educational and Therapeutic Center Qazvin Email: majidhajikarimi57@gmail.com Phone: 00982833332935 Fax: 00982833326033 Priority of response is as follows: Send written request via email Call or fax for further coordination Send postal letter if necessary Applicants are required to state their research objective and the type of analysis desired in the request. All requests will be authorized for scientific and research use after review and approval by the study investigator. How to obtain: Submitting a written request: The applicant must send an email or formal letter to the study investigator including the research objective, the type of analysis desired, and their contact information. Reviewing the request: The study investigator reviews the request and ensures that the proposed use is consistent with the scientific objectives of the study and complies with the principles of research ethics. Approval and conclusion of the agreement: If approved, the applicant is required to sign a confidentiality agreement and comply with the terms of use of data and documentation. Data preparation: De-identified data and documentation limited to the primary and secondary outcomes are prepared. Data delivery: Data is provided to the applicant via secure email, encrypted file, or secure download link. ⏱ Duration: The entire process from the time the request is submitted to the time the data is received usually takes about 4 to 6 weeks, depending on the volume of the request and the time it takes the study investigator to review it. Comments:
public Mohamad taghi pour
Boali hospital
Qazvin Iran (Islamic Republic of) 3413786165 +98 28 3333 2930 mohamad.taghipoor70@gmail.com Qazvin University of Medical Sciences scientific Mohamad taghi pour
Boali hospital
Qazvin Iran (Islamic Republic of) 3413786165 +98 28 3333 2930 mohamad.taghipoor70@gmail.com Qazvin University of Medical Sciences Iran (Islamic Republic of) patients with STEMI Abdicación clases 1 for ACE OR ARB 30 years 80 years Both I21.01 ST elevation (STEMI) myocardial infarction Treatment - Drugs Treatment - Drugs Intervention group: Telmisartan Intervention group: Valsartan Lipid profile including total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides. Timepoint: 3 m after starting the medication. Method of measurement: Blood sampling and serum testing with a standard blood biochemistry analyzer. Serum creatinine level and glomerular filtration rate (GFR) indicating kidney function. Timepoint: Before starting the medication and 3 m after starting the medication. Method of measurement: Blood sample and serum analysis with standard device. Systolic and diastolic blood pressure of patients. Timepoint: Before starting the medication, 4 weeks after starting the medication. Method of measurement: Standard mercury sphygmomanometer. Body mass index (BMI) of patients. Timepoint: Before starting the medication, 4 weeks after starting the medication. Method of measurement: Measuring height and weight with a standard scale and tape measure. Fasting blood glucose level. Timepoint: Before starting the medication, 4 weeks after starting the medication. Method of measurement: Blood sample and serum test with standard blood biochemistry analyzer. Adverse drug reactions. Timepoint: During the treatment period. Method of measurement: Questionnaire and clinical interview. Qazvin University of Medical Sciences Approved 2025-12-13 Ethics Committee of Qazvin University of Medical Sciences boali qazvin Qazvin Iran (Islamic Republic of)